14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Wed, 8 May 2024

Trading levels for DCTH

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.25 .
R2 10.25 .
R1 10.25 .
Current price: 10.25
Support S1 10.25 .
S2 10.25 .
S3 10.25 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 12.00 17.07 %
Current price 10.25
Support S1 8.30 -19.02%
S2 0 .
S3 0 .

DCTH Predictions History

7 years ago
JS predicted that DCTH for 2017-03-20 is going $0.102 (13.33%)

7 years ago
Jack.Cesario.Migueis.3576 predicted that DCTH for 2017-03-09 is going $0.153 (27.50%)

7 years ago
JS predicted that DCTH for 2017-03-07 is going $0.115 (-11.54%)

7 years ago
Blah predicted that DCTH for 2017-03-07 is going $0.120 (-14.29%)

Rank:

7 years ago
JS predicted that DCTH for 2017-03-06 is going $0.138 (-8.00%)

7 years ago
turki predicted that DCTH for 2017-03-06 is going $0.188 (25.33%)

Rank:

7 years ago
Jack.Cesario.Migueis.3576 predicted that DCTH for 2017-03-03 is going $0.320 (113.33%)

7 years ago
Turn.Around predicted that DCTH for 2017-03-03 is going $0.214 (42.67%)

Rank:

7 years ago
JS predicted that DCTH for 2017-03-03 is going $0.204 (36.00%)

7 years ago
Mina..Hanna.3544 predicted that DCTH for 2017-03-03 is going $0.500 (194.12%)

Rank:
Click to get the best stock tips daily for free!

About Delcath Systems

Delcath Systems Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS cli... DCTH Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT